Lilly (LLY.N) on Saturday presented Phase III results showing once-weekly
Retatrutide promoted weight loss and reduced severity of moderate-to-severe
obstructive sleep apnea by 60.6% and knee osteoarthritis pain by up to 73.1% in
obese adults.
2026-06-07
Lilly (LLY.N) on Saturday presented Phase III results showing once-weekly
Retatrutide promoted weight loss and reduced severity of moderate-to-severe
obstructive sleep apnea by 60.6% and knee osteoarthritis pain by up to 73.1% in
obese adults.